<DOC>
	<DOCNO>NCT00189969</DOCNO>
	<brief_summary>The purpose study assess take rate ( formation typical postvaccinal lesion ) safety immunogenicity smallpox vaccine Elstree-BN .</brief_summary>
	<brief_title>Take Rate , Immunogenicity Safety Elstree-BN Smallpox Vaccine Healthy Vaccinia-Naive Subjects</brief_title>
	<detailed_description />
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Smallpox</mesh_term>
	<criteria>Signed informed consent Free obvious health problem Negative HIV test Negative hepatitis B surface antigen negative antibody hepatitis C virus Hematocrit â‰¥ 38 % ; white blood cell 4.0 10.0 / nl differential blood count without clinical finding ; platelets 150 400 / nl ALT &lt; 1.5 time institutional upper limit normal Negative urine glucose dipstick urinalysis Adequate renal function define serum creatinine &lt; 1.5 mg/dL ; urine protein &lt; 100 mg/dL &lt; 2+ proteinuria ; calculate creatinine clearance &gt; 55 mL/min . For woman , negative pregnancy test screening within 24 hour prior vaccination . If volunteer female childbearing potential , agree use acceptable contraception . Pregnancy breastfeed Known suspect history smallpox vaccination Typical vaccinia scar Vaccinia specific antibody screen History immunodeficiency Known suspect impairment immunologic function Use immunosuppressive medication radiation therapy Any history atopic disease Eczema degree history eczema Chronic exfoliative skin disorders/conditions acute skin disorder large magnitude Any malignancy include leukemia lymphoma Presence infectious disease history evidence autoimmune disease History clinical manifestation clinically significant mental illness haematological , renal , hepatic , pulmonary , central nervous , cardiovascular gastrointestinal disorder History drug chemical abuse Administration inactivate vaccine 14 day prior vaccination Any immune modifying therapy within 4 week prior vaccination Administration live attenuate vaccine within 60 day prior vaccination Receipt blood product immunoglobulin past 6 month Subjects acute febrile illness within one week prior vaccination subject may incubation period infectious disease Household contacts/sexual contact , occupational exposure follow : 1 . Pregnant woman 2 . Children &lt; 12 month age 3 . People current history atopic dermatitis 4 . People chronic exfoliative skin disorders/conditions acute skin disorder 5 . People immunodeficiency disease , malignancy use immunosuppressive medication History anaphylaxis severe allergic reaction Hypersensitivity egg chick protein Known allergy component vaccine diluent Known allergy know component VIG Known allergy cidofovir probenecid Abnormalities suggestive underlie disease , detect routine test prior study inclusion Use investigational nonregistered drug vaccine start 30 day precede study vaccine end conclusion visit History myocardial infarction , angina , congestive heart failure , cardiomyopathy , stroke transient ischemic attack , heart condition care doctor . Three follow risk factor : An immediate family member onset ischemic heart disease age 50 year , elevate blood pressure , elevate blood cholesterol , diabetes nicotine abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>32 Years</maximum_age>
	<verification_date>April 2006</verification_date>
</DOC>